Avacta generates Affimer reagents for COVID-19 antigen rapid test ahead of schedule
Shares of Avacta Group (AIM: AVCT), the developer of Affimer biotherapeutics and reagents, were up more that 26% at 69.50 pence by early afternoon, after it announced that, in only four weeks and well ahead of schedule, it has successfully generated multiple Affimer reagents that bind the SARS-COV-2 viral antigen.
The development is part of Avacta’s collaboration with Cytiva (formerly GE Healthcare Life Sciences) to develop an Affimer-based rapid test for the COVID-19 coronavirus infection.
The process of generating new Affimer reagents to detect the SARS-COV-2 viral antigen was started in mid-March, shortly before the company announced its collaboration with Cytiva. Multiple highly specific Affimer binders have now been generated that bind to the spike proteins of the SARS-COV-2 virus and do not cross-react with other very closely related viruses, such as SARS and MERS.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze